TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from CLEO Diagnostics Ltd ( (AU:COV) ) is now available.
Cleo Diagnostics Ltd has received an A$845,000 cash refund from the Australian Government under the R&D Tax Incentive program, supporting their development of a diagnostic blood test for ovarian cancer. This financial boost strengthens Cleo’s position to advance its clinical trials in the U.S., aiming for FDA approval to enter the market, potentially transforming ovarian cancer diagnostics worldwide.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is a company focused on developing a simple blood test for the early and accurate diagnosis of ovarian cancer. Their technology is based on the novel patented CXCL10 biomarker, which is produced at high levels by ovarian cancers but is largely absent in non-malignant diseases. The company holds a worldwide exclusive license to commercialize this intellectual property, aiming to address the urgent clinical need for early detection of ovarian cancer.
YTD Price Performance: 25.00%
Average Trading Volume: 179,960
Technical Sentiment Signal: Strong Sell
For detailed information about COV stock, go to TipRanks’ Stock Analysis page.